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ABSTRACT Zika virus (ZIKV) has recently spread through the Americas and has been
associated with a range of health effects, including birth defects in children born to
women infected during pregnancy. Although the natural reservoir of ZIKV remains
poorly defined, the virus was first identified in a captive “sentinel” macaque monkey
in Africa in 1947. However, the virus has not been reported in humans or nonhuman
primates (NHPs) in Africa outside Gabon in over a decade. Here, we examine ZIKV
infection in 239 wild baboons and African green monkeys from South Africa, the
Gambia, Tanzania, and Zambia using combinations of unbiased deep sequencing,
quantitative reverse transcription-PCR (qRT-PCR), and an antibody capture assay that
we optimized using serum collected from captive macaque monkeys exposed to
ZIKV, dengue virus, and yellow fever virus. While we did not find evidence of active
ZIKV infection in wild NHPs in Africa, we found variable ZIKV seropositivity of up to
16% in some of the NHP populations sampled. We anticipate that these results and
the methodology described within will help in continued efforts to determine the
prevalence, natural reservoir, and transmission dynamics of ZIKV in Africa and else-
where.
IMPORTANCE Zika virus (ZIKV) is a mosquito-borne virus originally discovered in a
captive monkey living in the Zika Forest of Uganda, Africa, in 1947. Recently, an out-
break in South America has shown that ZIKV infection can cause myriad health ef-
fects, including birth defects in the children of women infected during pregnancy.
Here, we sought to investigate ZIKV infection in wild African primates to better un-
derstand its emergence and spread, looking for evidence of active or prior infection.
Our results suggest that up to 16% of some populations of nonhuman primate
were, at some point, exposed to ZIKV. We anticipate that this study will be useful
for future studies that examine the spread of infections from wild animals to hu-
mans in general and those studying ZIKV in primates in particular.
KEYWORDS false-positive reactions, Flavivirus, sensitivity and specificity,
seroepidemiologic studies, Zika virus, Zika virus infection
Zika virus (ZIKV) is a positive-sense single-stranded RNA virus (family Flaviviridae,genus Flavivirus) that recently emerged to cause widespread human infection in
Micronesia, French Polynesia, Singapore, and the Americas. The cause of ZIKV’s recent
global spread is poorly understood, and its natural reservoir remains poorly defined.
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ZIKV was first isolated from a captive rhesus macaque (Macaca mulatta) in Uganda in
1947 (1). Since then, ZIKV has been isolated from humans, monkeys, and mosquitoes
living in Africa, Southeast Asia, Micronesia, French Polynesia, and the Americas (2).
Monkeys in Africa often live in close association with humans and are likely involved in
the zoonotic transmission of flaviviruses, including ZIKV, mediated by mosquito vectors
(3). While previous serosurveys showed the presence of ZIKV in both humans and
nonhuman primates (NHPs) in Africa in the 1950s through 1980s, these surveys have
not since been updated, and ZIKV has not been reported in monkeys or humans in
Africa outside Gabon in over a decade (2, 3). In addition, past serosurveys were prone
to significant cross-reactivity with other flaviviruses, such as dengue virus (DENV), West
Nile virus (WNV), and yellow fever virus (YFV), complicating their interpretation (2–7).
Here we sought to better understand ZIKV prevalence in wild African primates using
unbiased deep sequencing, ZIKV-specific quantitative reverse transcription-PCR (qRT-
PCR), and a ZIKV-specific antibody capture assay, assessing for antibody cross-reactivity
to other flaviviruses using serum from experimentally infected macaque monkeys.
RESULTS
To investigate the prevalence of ZIKV and anti-ZIKV antibodies in wild African NHPs,
we obtained blood from four groups of NHPs: 14 Chacma-Kinda hybrid baboons (Papio
kindae  Papio ursinus griseipes) from Kafue National Park in Zambia, 41 yellow
baboons (Papio cynocephalus) from Mikumi National Park in Tanzania, 25 African green
monkeys (AGMs) from the Gambia (Chlorocebus sabaeus), and 159 AGMs sampled from
multiple sites across South Africa (Chlorocebus pygerythrus; see reference 8 for a
detailed map of sampling sites).
To assess the prevalence of active ZIKV infection, we performed unbiased deep
sequencing on a subset of NHP plasma samples described above. Sequencing did not
identify ZIKV reads in any of the samples investigated, although other RNA viruses,
including lentiviruses, pegiviruses, and arteriviruses, were detected (8–14).
We also assessed the prevalence of prior ZIKV infection by antibody capture
enzyme-linked immunosorbent assay (ELISA). Compared to captive ZIKV-naive baboons,
several wild baboons from Tanzania had significantly elevated levels of anti-ZIKV antibodies
(Fig. 1). In contrast, baboons from Zambia had no evidence of prior ZIKV exposure.
Similarly, several AGMs from The Gambia displayed evidence of prior ZIKV exposure
while those from South Africa had anti-ZIKV antibody levels comparable to those of
captive ZIKV-naive AGMs. None of the samples containing anti-ZIKV antibodies con-
tained ZIKV RNA as measured by highly sensitive quantitative RT-PCR (qRT-PCR).
A well-described problem in assessing ZIKV seroprevalence is the cross-reactivity of
antibodies to other flaviviruses with ZIKV antibody capture assays (2–7). To assess
whether the anti-ZIKV antibodies we detected in Tanzanian baboons and Gambian
AGMs were elicited by genuine ZIKV infection, we sought to rigorously characterize the
cross-reactivity of our ZIKV antibody capture assay. We tested sera from captive
macaques infected with DENV serotypes 1 to 4 as well as animals challenged with DENV
serotypes 1 to 4 after tetravalent vaccination to simulate repeated heterologous
exposure to flaviviruses closely related to ZIKV and found that these sera registered
with our ZIKV ELISA at levels above the manufacturer-recommended positivity thresh-
old of a change in optical density (ΔOD) of 0.3 (Fig. 1; see Table S1 in the supple-
mental material). However, sera frommacaques vaccinated with YFV registered at levels
comparable to uninfected animals. To control for cross-reactivity to DENV and reduce
the assay’s false-positive rate, we generated a receiver operating characteristic (ROC)
curve and determined a positivity threshold based on empirical data from captive
macaques (Fig. 1B). The area under this curve, 0.9989, indicated that the assay could
consistently distinguish between samples from ZIKV-exposed and ZIKV-naive animals,
even those repeatedly and recently exposed to DENV. The optimal positivity threshold,
ΔOD of1.445, showed a specificity of 98.9% and a sensitivity of 100%. To validate our
sample set at this threshold, we blindly tested sera from ZIKV-exposed and ZIKV-naive
animals and were able to accurately determine their exposure history (see Fig. S1 in the
Buechler et al.
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supplemental material). At this threshold, 4 of 25 (16%) Gambian AGMs showed
evidence of prior exposure to ZIKV, while 2 of 41 (4.9%) Tanzanian baboons tested
positive for anti-ZIKV antibody (Fig. 1C; see Table S2 in the supplemental material).
DISCUSSION
We assessed the prevalence of ZIKV exposure in four wild primate populations in
Africa: baboons (genus Papio) from Tanzania and Zambia and AGMs (genus Chloroce-
bus) from South Africa and the Gambia. We saw no evidence of active infection, but our
results suggest prior ZIKV exposure in Tanzanian baboons and Gambian AGMs. As ZIKV
causes an acute viral infection in nonpregnant NHPs and humans, the lack of active
ZIKV infection in this cross-sectional study is not entirely surprising. Additionally, our
use of qRT-PCR and unbiased deep sequencing enabled us to rule out the presence of
low-titer ZIKV infection as well as the presence of other flaviviruses circulating in these
NHP populations at the time of sampling. Nevertheless, these methods do not rule out
the possibility of low-copy-number infection with other flaviviruses, although such
courses are not typical of ZIKV or closely related flaviviruses.
FIG 1 ZIKV ELISA results by NHP type and prior exposure. (A) Reactivity of the anti-ZIKV antibody capture ELISA to serum/plasma collected
from macaques (yellow), AGMs (green), and baboons (blue). Anti-ZIKV antibody titers were compared among different groups within each
NHP genus using a two-tailed unpaired t test. For macaques, these data were also used to generate the receiver operating characteristic
(ROC) curve. The geographic region from which samples were collected from wild NHPs is indicated in the maps under each column. (B)
ROC curve, plotting the true-positive rate (TPR; sensitivity) against the false-positive rate (FPR; 1 specificity) for potential discrimination
thresholds. Units are presented here as percentages rather than fractions. Potential discrimination thresholds were found by sorting all
of the values from captive macaques and averaging adjacent values. The area under the curve (AUC) indicates the ability of the test to
discriminate between primates with ZIKV and those without, with a perfect test having an AUC of 1 and a test with no ability to
discriminate having an AUC of 0.5. Both AUC and the significance compared to a test with an AUC of 0.5 were computed using GraphPad
Prism (GraphPad Software, Inc., La Jolla CA). The potential discrimination value that maximized the likelihood ratio (TPR/FPR) was 1.445,
and this value was adopted as the empirical positivity threshold, depicted by the dashed line in panel A. (C) Data points above the dashed
line in panel A were deemed “positive” and used to estimate the prevalence of ZIKV exposure in each population.
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We observed a range of anti-ZIKV antibody titers in wild NHPs. Several factors could
account for this wide range in antibody titers, including waning immunity from a ZIKV
infection in the distant past, infection with a flavivirus that elicits an antibody response
that cross-reacts with our ZIKV antibody capture assay (e.g., DENV), or repeated flaviviral
infections that might increase the avidity of pan-flaviviral antibodies. While we assessed
cross-reactivity in this assay using samples from animals previously exposed to either
DENV or YFV, two flaviviruses known to cross-react in ZIKV antibody capture assays, it
should be noted that there are many other flaviviruses present in nature with the
potential to elicit antibodies that may cross-react with this assay. Nonetheless, the
empirically derived positivity threshold for our anti-ZIKV ELISA, based on samples from
animals infected with ZIKV or closely related flaviviruses, and our validation of this
method suggest that the antibodies we detected in wild NHPs were elicited by genuine
ZIKV infection. The ZIKV seroprevalence estimates reported here are well below many
of those noted in previous studies (2), possibly reflecting the lower false-positive rate
of this method and providing a more accurate estimate of the incidence of ZIKV
infection in the NHP communities surveyed.
We saw more ZIKV-exposed animals in NHPs from the northern areas of sub-Saharan
Africa, even given the more extensive sampling performed on similar species in
southern Africa (Fig. 2). These results suggest that the distribution of ZIKV infection may
be determined more by environmental or geographical factors, such as the prevalence
of particular mosquito vectors or tropical forest conditions, than host species, although
further work is needed to substantiate this hypothesis. We also saw evidence of ZIKV
infection in areas of Africa where ZIKV has not been reported in humans or primates in
FIG 2 Geographic representation of ZIKV detection in wild African primates. Countries where human
ZIKV infection has been previously detected are shown in blue, countries where human and nonhuman
primate ZIKV infection have both been previously detected are shown in brown, locations in which
nonhuman primate ZIKV infection was detected in the present study are shown with red dots, and
locations in which nonhuman primate ZIKV infection was not detected in the present study are shown
with yellow dots. A review of previous serosurvey studies can be found in reference 2.
Buechler et al.
March/April 2017 Volume 2 Issue 2 e00392-16 msphere.asm.org 4
over a decade (2, 3), potentially pointing to a persistent and previously unrecognized
reservoir. Ultimately, we believe that the methods reported here will be useful for larger
serosurveys of wild animals to more accurately determine the prevalence of ZIKV
infection. Such studies will be vital for further understanding the natural reservoir and
transmission dynamics of ZIKV in Africa and elsewhere.
MATERIALS AND METHODS
Sample collection. Four populations of wild nonhuman primates were included in this study—
African green monkeys (AGMs) from across South Africa (Chlorocebus pygerythrus) and the Gambia
(Chlorocebus sabaeus) and baboons from Kafue National Park in Zambia (Kinda  Chacma hybrid
baboons [Papio kindae  Papio ursinus griseipes]) and Mikumi National Park in Tanzania (yellow baboons
[Papio cynocephalus]). All research involving nonhuman primates was conducted according to regula-
tions set forth by the Animal Welfare Act and approved by the appropriate wildlife authorities and
institutional animal care and use committees. Briefly, all animals were sedated prior to blood collection
and were released back to their social group without incident following sample collection and recovery
from anesthesia. After initial collection, samples were stored on dry ice, in liquid nitrogen, or otherwise
below 40°C. Sampling of AGMs was approved by the Interfaculty Animal Ethics Committee (project no.
13/2010) at the University of the Free State and by the University of Wisconsin—Milwaukee Animal Care
and Use Committee (protocol 07-08 32) using methods described previously (15). Sampling of yellow
baboons in Tanzania was performed using standard methods for field studies of baboons as described
previously (16). The field work in Tanzania was reviewed and approved by The Tanzanian National
Scientific Research Council, the Serengeti Wildlife Institute, Tanzanian National Parks, Washington
University, and Yale University, with additional approval through United States NSF grant BNS83-03506.
Sampling of hybrid Kinda  grayfooted-Chacma baboons in Zambia was performed in compliance with
the rules of the Zambian Wildlife Authority and the rules of the animal care and use committees from
Baylor College of Medicine (AN-5538), Washington University School of Medicine (protocol 20120269),
New York University (protocol 10-1349), and applicable national laws. Samples from Tanzania were
collected in 1985 and 1986; samples from the Gambia, South Africa, and Zambia were collected between
2010 and 2014.
Deep sequencing. Samples from South Africa, Zambia, and Tanzania were processed for deep
sequencing as described previously (13). Briefly, viral RNA was isolated from approximately 200 l of
plasma, and cDNA synthesis was primed using random hexamer primers. Samples were fragmented, and
sequencing adaptors were added using a Nextera DNA sample preparation kit (Illumina, San Diego, CA).
Deep sequencing was performed on an Illumina MiSeq. Sequence data were analyzed using CLC
Genomics Workbench (version 6.5) software (CLC Bio, Aarhus, Denmark) and Geneious R9 software
(Biomatters, Auckland, New Zealand). Low-quality reads (Phred quality score of Q30) and short reads
(100 bp) were removed. Samples were then compared against all viral sequences in the NCBI GenBank
database as of 22 June 2016 (17) using BLAST.
ELISA. All samples were tested for ZIKV-specific immunoglobulin G (IgG) against recombinant ZIKV
nonstructural protein 1 (NS1) using ELISA kits designed by XPressBio (Frederick, MD). Samples were
diluted 1:50, and the assay was performed according to the manufacturer’s instructions, with all tests
performed in duplicate. Briefly, diluted samples were applied to wells precoated with ZIKV NS1 protein
or a negative-control antigen. After incubation and washing with a Tris buffer, a secondary anti-simian
antibody conjugated to horseradish peroxidase was added. This substrate was visualized after another
incubation and wash step with the addition of ABTS [2,2=-azinobis(3-ethylbenzthiazolinesulfonic acid)]
peroxidase substrate. Test values were determined by subtracting the optical density (OD) at 405 nm of
the well precoated with negative-control antigen from that of the well precoated with ZIKV NS1,
resulting in a ΔOD value for each test. In addition to the samples from wild African primates, groups of
baboons (n  25) and AGMs (n  16) were also tested after being raised in captivity with no known
flaviviral exposure. Rhesus macaques (Macaca mulatta) were tested after being infected with the African
strain of ZIKV (ZIKV-MR766; n  3) or the French-Polynesian/South American strain of ZIKV (ZIKV-FP; n 
7), vaccinated for YFV (n  6), or infected with DENV without prior vaccination (DENV-1 [n  6], DENV-2
[n  6], DENV-3 [n  12], DENV-4 [n  6]). A group of cynomolgus macaques (Macaca fascicularis) was
tested after DENV-1 (n  4), DENV-2 (n  4), DENV-3 (n  4), or DENV-4 (n  4) challenge following
administration of a tetravalent DENV vaccine, simulating repeated heterologous exposure to multiple
flaviviruses closely related to ZIKV. Four of the unexposed and four of the ZIKV-FP-infected rhesus
macaques were tested separately in a blind confirmation of the experimentally determined positivity
criterion. Exposure dates ranged from 2 years to 2 months prior to sample collection for both experi-
mentally infected and vaccinated animals.
qRT-PCR. Seven samples from the Gambia and one from South Africa that tested above the
manufacturer-recommended ELISA threshold of an ΔOD of 0.3 were also subjected to highly sensitive
qRT-PCR to discern whether viral RNA was still present. Similar samples from Tanzania were not included
due to sample availability. No samples from Zambia tested above the manufacturer-recommended
positivity threshold. The qRT-PCR was performed as described previously (18), using the SuperScript III
Platinum one-step qRT-PCR system (Invitrogen, Carlsbad, CA) on the LightCycler 480 instrument (Roche
Diagnostics, Indianapolis, IN), with forward primer CGYTGCCCAACACAAGG, reverse primer CCACYAAYG
TTCTTTTGCABACAT, and probe AGCCTACCTTGAYAAGCARTCAGACACYCAA (19). The virus concentration
was determined by interpolation onto an internal standard curve composed of seven 10-fold serial
dilutions of a synthetic ZIKV RNA fragment based on ZIKV strain H/PF/2013.
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